Next Article in Journal
Febrile Neutropenia Rates with Adjuvant Docetaxel and Cyclophosphamide Chemotherapy in Early Breast Cancer: Discrepancy between Published Reports and Community Practice—An Opdated Analysis
Previous Article in Journal
Ubiquitin Pathway and Ovarian Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 6
10.3747/co.19.1224
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines

by
J. Klein–Geltink
1,
T. Forte
1,*,
R. Rahal
1,
J. Niu
1,
D. He
1,
G. Lockwood
1,2,
W. Cheung
3,
G. Darling
4 and
H. Bryant
1,5
1
Canadian Partnership Against Cancer, Toronto, ON, Canada
2
Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
3
BC Cancer Agency, Vancouver, BC, Canada
4
Toronto General Hospital, University Health Network, Toronto, ON, Canada
5
‖ Departments of Community Health Sciences and Oncology, University of Calgary, Calgary, AB, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(6), 329-331; https://doi.org/10.3747/co.19.1224
Submission received: 6 September 2012 / Revised: 4 October 2012 / Accepted: 2 November 2012 / Published: 1 December 2012

Abstract

As part of the system performance initiative of the Canadian Partnership Against Cancer, indicators measuring treatment practice patterns across the country relative to evidence-based guidelines were first published in 2010 and are updated annually. Among the treatment indicators examined is the percentage of resected stage ii and iii rectal cancer patients receiving neoadjuvant (preoperative) radiation therapy (RT), the treatment approach recommended for locally advanced rectal cancer

Share and Cite

MDPI and ACS Style

Klein–Geltink, J.; Forte, T.; Rahal, R.; Niu, J.; He, D.; Lockwood, G.; Cheung, W.; Darling, G.; Bryant, H. A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines. Curr. Oncol. 2012, 19, 329-331. https://doi.org/10.3747/co.19.1224

AMA Style

Klein–Geltink J, Forte T, Rahal R, Niu J, He D, Lockwood G, Cheung W, Darling G, Bryant H. A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines. Current Oncology. 2012; 19(6):329-331. https://doi.org/10.3747/co.19.1224

Chicago/Turabian Style

Klein–Geltink, J., T. Forte, R. Rahal, J. Niu, D. He, G. Lockwood, W. Cheung, G. Darling, and H. Bryant. 2012. "A Retrospective Chart Review Validates Indicator Results and Provides Insight into Reasons for Non-Concordance with Evidence-Based Guidelines" Current Oncology 19, no. 6: 329-331. https://doi.org/10.3747/co.19.1224

Article Metrics

Back to TopTop